By Justin Yamashita, MSc. Benchtop, site, CRO: three levels of basic and clinical research, explained without spin.

Open Label Media, the team of one behind Root to Rx, comes a quiz to find out your type of skepticism, plus two free interactive games for telling what's true. Stay in the Room shows you how to disagree without a fight, so when the moment matters, you're ready to have the talk. Got Skepticism? runs any claim through a five-move toolkit to test whether your confidence is earned. All three play in your browser in about two minutes at openlabelmedia.com, and I'd love to see your results on social media.

100 subscribers. That's not a Root to Rx milestone, that's a #SkepticalRevolution milestone, because every one of you got here by someone else sharing it. Keep spreading the word, click around the links in this issue, and if there's a topic you want dug into, just hit reply.

The Informed is normally a web-only companion, but this issue earned an exception. It goes out as a special edition email tonight at 6 PM ET, the most detailed look yet at how the clinical research industry actually works, built to remove the mystery, not add to it. This is not our new normal, just this once, because this issue was worth putting in your inbox.

From Issue 012

Issue 012 named what the pharmaceutical industry gets wrong, specifically and with documentation. Pay-for-delay, Patent thickets, Ghost-writing, Selective publication, Shkreli, and The Sacklers. The list is real and ever growing.

Issue 013 asks one follow-on question: if that is the standard you are applying to pharma, where is it when you buy a supplement or some other wellness product?

The Other Industry

The global dietary supplement industry generates more than $200 billion a year in revenue.

It’s not a cottage industry of small producers making honest products. It’s a large, commercially motivated industry that benefits financially from the claim that its products are safer and more rigorously tested than regulated alternatives.

Run Q4 before you read anything in this issue: who benefits if you believe that pharmaceutical drugs are inherently suspect and supplements are inherently safe?

What DSHEA Actually Says

In 1994, the US Congress passed the Dietary Supplement Health and Education Act (DSHEA). This established the current regulatory framework for supplements in the United States. Its core provision: supplement manufacturers are not required to prove safety or efficacy before bringing a product to market. The burden is reversed. The FDA must prove a supplement is unsafe in order to restrict it.

This is the opposite of how pharmaceutical drugs are regulated. A drug cannot reach market without clinical trial data demonstrating it is safe and effective. A supplement can reach market on the manufacturer’s own determination that it is generally recognized as safe.

What this means in practice: a supplement has no required Phase I, Phase II, or Phase III trial data. No independent data safety monitoring board reviewed it. No FDA advisory committee voted on it. No statistical review team analyzed the efficacy data. The pharmacist at the counter has no required efficacy data to reference when answering questions about it.

Berberine and the ‘Natural Ozempic’ Claim

Berberine is a plant compound that has been studied for its effects on blood glucose. In some studies, it has shown glucose-lowering effects. Social media influencers and wellness platforms have marketed it as a ‘natural Ozempic’ or ‘natural GLP-1.’

This framing requires a correction. GLP-1 receptor agonists (chemicals that bind to a specific target like a lock being the target, the agonist is the key) such as semaglutide, tirzepatide, work by binding to a specific receptor that triggers insulin release, slows gastric emptying, and reduces appetite. Their mechanism is precise and their effects on weight and blood glucose are documented in large randomized controlled trials with tens of thousands of patients.

Berberine’s primary mechanism involves AMPK activation. It is not a GLP-1 receptor agonist. It does not bind the same receptor. The effects overlap in a general direction, both can lower blood glucose in some populations, but ‘natural Ozempic’ implies a molecular equivalence that does not exist.

The clinical evidence for berberine in glucose management exists. It is not comparable in size, rigor, or regulatory review to the evidence base for approved GLP-1 receptor agonists. That’s the comparison being hidden by the ‘natural Ozempic’ label.

This is the exact pairing the pharmacist stops to flag in this week’s Root Room: berberine stacked on top of metformin, both lowering glucose, with nobody at the prescribing end told.

Peptides: The Clearest Example of the Inverted Standard

Research peptides, BPC-157, TB-500, CJC-1295, ipamorelin, and others, are sold online with the label ‘for research purposes only, not for human consumption.’ They’re injected by people who fear vaccine side effects and distrust FDA-approved medications.

BPC-157 has animal data suggesting tissue-healing properties. It has no FDA approval, remains an investigational compound, and to my knowledge has no published human safety trial at the time of publishing this newsletter, July 2026. A 2025 systematic review of the BPC-157 literature identified 36 studies, 35 in animals and only 1 in humans, and found no clinical safety data at all.

The manufacturing standard for research peptides is not GMP, the Good Manufacturing Practice standard that pharmaceutical facilities must meet. It’s the standard of a research chemical lab, which varies considerably. The same person who will not take a vaccine because of a one-in-a-million adverse event rate is injecting a compound that has never had a human adverse event rate calculated at all.

Run the Skeptic’s Toolkit Q5: Is the same standard being applied to both?

Myth: ‘Supplements Are Natural, Therefore Safer Than Drugs’

‘Natural’ is a marketing category, not a pharmacology category. Digitalis is natural. Arsenic is natural. Botulinum toxin is natural. The word describes origin, not effect or safety profile.

Prescription medications go through extensive testing specifically to characterize their safety profile, what they do, at what dose, in what populations, with what interactions. A supplement’s safety profile is frequently unknown, because the testing that would reveal it was not required before the product went on sale.

The absence of documented side effects is not the same as the absence of side effects. It often means nobody was required to look.

This is not hypothetical. Red yeast rice contains monacolin K, a compound molecularly identical to the prescription statin lovastatin, so taking it alongside a statin or certain other drugs can stack a dose you did not know you were taking. Rhabdomyolysis, a dangerous breakdown of muscle tissue, has been documented from exactly this kind of combination.

St. John’s Wort runs the other direction: it speeds up the liver enzyme that clears many medications, which has pushed transplant patients’ anti-rejection drug levels low enough to trigger organ rejection. Same lesson both times. A supplement is not inert just because you can buy it without a prescription.

Running the Skeptic’s Toolkit

Q1: What evidence would actually change my mind?

If you take a supplement and believe it is working, ask this question seriously. What evidence would convince you it is not working, or is causing harm? If no evidence would change your mind, that is worth noticing.

Q5: Am I applying the same standards to all claims?

The standard applied to pharmaceutical drugs in mainstream skepticism, clinical trials, peer review, regulatory approval, is not routinely applied to supplements. The standard applied to supplements, ‘it worked for me,’ ‘it is natural,’ ‘my friend recommends it’, would not survive contact with Q5 if applied to a vaccine.

The Action Step This Issue

Create the list of everything you are currently taking, prescriptions, over-the-counter, supplements, herbs, powders, peptides. We made templates to help paint the full picture for your doctors: Medication and Supplement log, Medical History Log, Symptom Log, and even a special pediatric special symptom tracker with the help of @ali_the_peds_np. Ask whether your doctor knows about all of it, and if any of it is interacting or interfering. Next issue, we will give you the tool clinical research uses to track exactly this.

Next Issue

Fewer than 50% of patients tell their doctor about their supplements. The clinical research world has a standard instrument for this. We adapted it for patients, and will show how to use it.

This Week in The Root Room

Debby walks into a pharmacy with a bag she bought online. The pharmacist behind the counter is not going to tell her to throw it out. She is going to ask her something harder.

Dr. Anecdote is in the supplement aisle with 2.4 million reasons to be there.

This Week in The Informed

The depth companion goes up the same day. DSHEA in full, the gap between pharmaceutical GMP and a research-chemical lab, the documented drug-supplement interactions (St. John’s Wort, red yeast rice, berberine, kava), and why the testimonial format is built to sell rather than to test.

Read both, The Root Room and The Informed, on the web.

New here? Start with these 3 issues.

Issue 001: Why Your Distrust Is Rational. The founding argument. Why skepticism is healthy and how to channel it.

Issue 003b: Vaccine Myths, Set Straight. The Skeptic’s Toolkit, the 10 questions you will use on everything.

Issue 004: From Molecule to Medicine. The map of how drugs get built, tested, and approved.

References

Dietary supplement market size: Grand View Research, Dietary Supplements Market Report, 2025 (estimated USD 209.5 billion). grandviewresearch.com/industry-analysis/dietary-supplements-market-report

DSHEA 1994 framework: NIH Office of Dietary Supplements. ods.od.nih.gov/About/DSHEA_Wording.aspx

FDA, Questions and Answers on Dietary Supplements. fda.gov/food/information-consumers-using-dietary-supplements/questions-and-answers-dietary-supplements

Berberine mechanism and evidence (AMPK activation, modest glucose effect, not a GLP-1 receptor agonist): review in PMC. ncbi.nlm.nih.gov/pmc/articles/PMC12735998/

BPC-157 regulatory status: not FDA approved and not on the 503A compounding Bulks List as of July 2026. FDA’s Pharmacy Compounding Advisory Committee is scheduled to review BPC-157 (free base and acetate) for possible 503A Bulks List inclusion on July 23, 2026 (use FDA evaluated: ulcerative colitis; docket FDA-2025-N-6895). Confirm the outcome if publishing after that date. fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026

Berberine, glucose-lowering effect and hypoglycemia risk (meta-analysis of 37 randomized trials, n=3,048; effect is glucose-dependent and did not significantly increase hypoglycemia risk): Xie et al., Frontiers in Pharmacology, 2022. doi.org/10.3389/fphar.2022.1015045

BPC-157, near-absence of human data (systematic review: 36 studies, 35 preclinical and 1 clinical, no clinical safety data found): Vasireddi et al., HSS Journal, 2025. doi.org/10.1177/15563316251355551

BPC-157, not approved and widely sold online (literature and patent review): Jozwiak et al., Pharmaceuticals (Basel), 2025. doi.org/10.3390/ph18020185

Red yeast rice contains monacolin K, molecularly identical to the statin lovastatin; documented rhabdomyolysis in a transplant patient who combined it with cyclosporine: Prasad et al., Transplantation, 2002. doi.org/10.1097/00007890-200210270-00028

Red yeast rice, serious adverse events (rhabdomyolysis, acute hepatitis) from FDA and EFSA reporting systems, rare but documented: Banach and Norata, Current Atherosclerosis Reports, 2023. doi.org/10.1007/s11883-023-01157-4

St. John’s Wort lowers cyclosporine levels and has caused organ transplant rejection (systematic review of case reports and series): Ernst, Archives of Surgery, 2002. doi.org/10.1001/archsurg.137.3.316

Herbal and dietary supplements now account for about 20 percent of drug-induced liver injury cases in the U.S. Drug-Induced Liver Injury Network: Halegoua-DeMarzio and Navarro, Liver International, 2024. doi.org/10.1111/liv.16071

Welcome to the Skeptical Revolution. This is a growing community learning to tell hype from evidence together, one issue at a time, and you’re part of it now. If Root to Rx isn’t in your inbox yet, subscribe at the top of this page so the next issue finds you. New here? Take the two-minute Skeptic Type quiz at openlabelmedia.com/skeptic-type to see how you read a claim. Then come think out loud with us: the Root to Rx Lab on Facebook, and @roottorx on Instagram. #SkepticalRevolution

ABOUT OPEN LABEL MEDIA

Root to Rx is part of Open Label Media LLC. Open label is a clinical trial term for a study that hides nothing: no blinding, no hidden group, no sleight of hand. That is the whole point of what we build. Open Label Media exists for evidence literacy, in the open, with no agenda. Root to Rx points that openness at the clinical research world, which is much bigger than the drug companies: the sites, doctors, coordinators, nurses, CROs, scientists, biostatisticians, and regulators who actually run it. You will meet them in the issues ahead.

openlabelmedia.com

The views expressed on Root to Rx are my own and do not represent the views or positions of my employer, or any affiliated organization.

Root to Rx  |  228 Park Ave S, #29976, New York, New York 10003, United States

You are receiving this because you subscribed at roottorx.com.